| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.0008 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0008 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0008 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0009 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.17 | 0.001 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |